Decreased levels of circulating sex hormones as a biomarker of lung cancer in male patients with solitary pulmonary nodules

Gu, Tao; Wen, Zongmei; Xu, Shufeng; Hua, H J; Zhang, Zhi; Wen, Tao; Fu, Zhanzhao; Lv, Xin

doi:10.4314/ahs.v14i2.10

Cited by 4 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 However, a small hospital-based study found lower concentrations of circulating testosterone and estradiol in male patients with lung cancer compared to normal controls and patients with benign pulmonary nodules. 39 The present study prospectively demonstrated that higher concentrations of circulating free testosterone was associated with lower risk of lung cancer in postmenopausal never-smoking women. However, our study failed to show an independent association between baseline concentrations of estrogens and subsequent risk of lung cancer.…”

Section: Discussionsupporting

confidence: 50%

“…Further, androgen deprivation therapy in prostate cancer patients had been associated with a lower risk of second primary lung cancer in a US veteran study 38 . However, a small hospital‐based study found lower concentrations of circulating testosterone and estradiol in male patients with lung cancer compared to normal controls and patients with benign pulmonary nodules 39 . The present study prospectively demonstrated that higher concentrations of circulating free testosterone was associated with lower risk of lung cancer in postmenopausal never‐smoking women.…”

Section: Discussionmentioning

confidence: 43%

See 1 more Smart Citation

Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never‐smoking women

Zhao

Gao

Zhang

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Although reproductive factors have been repeatedly associated with lung cancer risk, no study to date has directly evaluated the relationship with endogenous sex hormones nor with aromatase activity in postmenopausal never-smoking women. A case-control study of 397 incident lung cancer cases and their individually matched controls, nested within the Shanghai Women's Health Study, was conducted among postmenopausal women who were lifetime never smokers. Prediagnostic concentrations of sex hormones was quantitated using LC-MS/MS assays in plasma. The product-substrate molar ratio of estrone to androstenedione was used as an index of aromatase activity (IAA). Multivariable conditional logistic regression models were used to calculate odds ratios (ORs) for lung cancer. Baseline concentrations of estradiol, free testosterone and IAA were inversely associated with subsequent risk of lung cancer in multivariable-adjusted models. When further adjusted for body mass index, the inverse association with estradiol was attenuated and no longer statistically significant, but the association with free testosterone and IAA remained. In analyses confined to participants having never used menopausal hormone therapy in 376 case-control pairs, the inverse association with free testosterone and IAA was slightly strengthened. OR for the highest vs the lowest quartile of free testosterone was 0.55 (95% CI = 0.34-0.90; P trend = .03), and the corresponding OR for IAA was 0.57 (95% CI = 0.34-0.96; P trend = .04). Our study, for the first time, suggests that higher levels of circulating free testosterone and estimated aromatase activity may be associated with lower lung cancer risk in postmenopausal never-smoking women.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 43%

Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never‐smoking women

Zhao

Gao

Zhang

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Furthermore, the sensitivity of biomarkers used in lung cancer screening are generally low. In one study, only 8 out of 47 patients with malignant solitary pulmonary nodules had elevated CEA levels that belonged to lung adenocarcinoma [11].…”

Section: Discussionmentioning

confidence: 98%

“…In addition, elevation of some of the biomarkers were found not only in lung cancer, but also they were detected abnormally in other diseases [8][9][10]. It is still unclear what the optimal combination of tumor biomarkers to enhance the diagnostic e cacy, the ability of tumor markers in characterizing the histological type of lung cancer are still unclari ed [11]. Furthermore, evaluation of the new potential biomarkers for lung cancer are needed for a better diagnosis, therapeutic monitoring, and prognostication of lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Histological specificity and diagnostic performance of a six-biomarker panel of lung cancer: An evaluation of a geographically-based multicenter study in China

Li¹,

Zhang²,

Jiang³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Lung cancer is the most common neoplasm among all cancers worldwide. Early diagnosis with minimal invasive procedures is ideal for lowering the patients’ burden and increasing survival rates. The value of serum tumor biomarkers used in lung cancer screening is still controversial in clinical practice.Methods: Serum levels of ProGRP, NSE, SCC-Ag, CEA, CYFRA21-1, and HE4 were measured using the chemiluminescence immunoassay in apparently healthy Chinese individuals, as well as in those with benign non-cancerous diseases, lung cancer patients, and those suffering other types of malignancies. Data was analyzed utilizing the SPSS version 18.0 statistical software. Results: All 6 serum biomarkers in lung cancers were significantly higher than in benign non-cancerous diseases and healthy controls. HE4 levels in benign diseases were significantly higher than in healthy controls. SCC-Ag, CEA, and CYFRA21-1 levels in lung cancers were significantly higher than in other malignancies. ProGRP and NSE levels in SCLC were significantly higher than in other histologic types; SCC-Ag and CYFRA21-1 levels in SCC were significantly higher than in other histologic types; the HE4 level in SCLC was also significantly higher than in SCC and adenocarcinoma, while adenocarcinoma had the highest serum CEA level comparing to SCC and SCLC. Serum ProGRP, NSE, and HE4 in SCLC were significantly higher than in NSCLC, SCC-Ag level in NSCLC was significantly higher than in SCLC. All biomarkers in advanced stages were significantly higher than in lower stages. NSE, HE4, and ProGRP presented relative high performance in SCLC. CYFRA21-1, HE4, and SCC-Ag indicated relative high performance in SCC. All biomarkers had relatively low performance on adenocarcinoma histologic type. The best performance of 2-marker combination was SCC-Ag+CYFRA21-1 for SCC, ProGRP+NSE for SCLC, CEA+CYFRA21-1 for adenocarcinoma. A combination of SCC+CEA+CYFRA21-1 gained highest performance for NSCLC.Conclusions: A 6-biomarker panel had capability on characterizing lung cancer and presented high performance individually and combinatorically on different histologic types of the neoplasm. HE4 showed high sensitivity to all histologic types of the malignancy; however, one should be cautious since its level also increased in benign non-cancerous diseases.

show abstract

The impact of thoracotomy on psychological and sexual function in men with lung cancer

Bolat

Çelik

et al. 2019

Revista Internacional de Andrología

View full text Add to dashboard Cite

Decreased levels of circulating sex hormones as a biomarker of lung cancer in male patients with solitary pulmonary nodules

Cited by 4 publications

References 19 publications

Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never‐smoking women

Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never‐smoking women

Histological specificity and diagnostic performance of a six-biomarker panel of lung cancer: An evaluation of a geographically-based multicenter study in China

The impact of thoracotomy on psychological and sexual function in men with lung cancer

Contact Info

Product

Resources

About